Robert Allaway is a senior scientist at Sage Bionetworks. The majority of his research involves applying computational methods to the study of neurofibromatosis type 1, type 2, and schwannomatosis (NF). Most recently, his work has focused on identifying challenges and opportunities in genomic analysis of rare tumor data from NF, as well as designing and implementing bioinformatic analyses for data derived from NF tumor models. In addition to his research role, he also leads other projects with the broad goal of promoting open science approaches in biomedical research and crowdsourced algorithm development and benchmarking (DREAM Challenges). Recent examples of drug discovery and medical imaging DREAM Challenges in which he has been involved in include: Illuminating the Druggable Genome-DREAM Drug Kinase Binding Prediction Challenge, Multi-Targeting Drug DREAM Challenge, CTD2 Pancancer Drug Activity DREAM Challenge, CTD2 Pancancer Chemosensitivity DREAM Challenge, and the Rheumatoid Arthritis 2 DREAM Challenge.